IP Library Granted Patent US 7,844,425
Granted Patent B2
US 7,844,425 · App. 12/016,857 · Granted Nov 30, 2010

Finite element modeling of the cornea

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,844,425
App. No.
12/016,857
Granted
Nov 30, 2010
Kind
B2
Abstract

A system and method for simulating a corneal reconfiguration in response to LIOB uses a computer-programmed, finite element model. The model has a plurality of elements; with each element pre-programmed with coefficients based on diagnostic corneal data. Collectively the coefficients replicate biomechanical properties of the cornea. In use, designated biomechanical characteristics on a plurality of selected elements (i.e. selected coefficients) are minimized to simulate LIOB in an actual cornea. A computer then measures the resultant reconfiguration of the cornea model to assess an actual cornea's response to LIOB.

Claims (144)

1. A system for simulating a reconfiguration of a model cornea which comprises:

a computer programmed with a finite element model, wherein the finite element model defines an anterior surface and a posterior surface for the cornea, with an axis perpendicular to the surfaces and passing through respective apexes of the surfaces, and further wherein the curvatures of the anterior and posterior surfaces are approximated by a respective conic section, and the finite element model includes a plurality of elements, wherein a first group of elements are pre-programmed with coefficients to simulate biomechanical characteristics for Bowman's capsule of the cornea and a second group of elements are pre-programmed with coefficients to simulate biomechanical characteristics for a stroma of the cornea, and further wherein the pre-programmed elements of the first and second groups are established for the finite element model according to diagnostic corneal data;

a computer means for reducing coefficients of the finite element model into a range approximately eighty to ninety-five percent of the preprogrammed value to minimize designated biomechanical characteristics on at least one selected element to create a reconfigured model cornea; and

a computer means for measuring the reconfigured model cornea.

2. A system as recited in claim 1 wherein the conic section for each surface is expressed as:

z

(

x

)

=

1

2

-

1

[

R

2

+

x

2

(

2

-

1

)

-

R

]

3. A system as recited in claim 2 where:

R for the anterior surface is approximately 7.86 mm;

R for the posterior surface is approximately 6.76 mm; and

e for the eccentricity of the cornea is 0.32.

4. A system as recited in claim 1 wherein each element is three dimensional and includes tensors having stress-strain coefficients.

5. A system as recited in claim 1 wherein the finite element model defines nine layers of elements wherein three of the layers include the first group of elements, and six of the layers include the second group of elements.

6. A system as recited in claim 1 wherein the first computer means simulates a cut inside the stroma, substantially parallel to the axis.

7. A system as recited in claim 1 wherein the first computer means simulates a cut inside the stroma, substantially perpendicular to the axis.

8. A system as recited in claim 1 wherein the finite element model is axisymmetric and is based on a nonlinearly elastic, slightly compressible, transversely isotropic formulation with an isotropic exponential Lagrangian strain-energy function based on:

W =½ C ( e Q −1)+ C compr ( I 3 InI 3 −I 3 +1)

and

Q=b ff E 2 ff +b xx ( E 2 cc +E 2 ss +E 2 cs +E 2 sc )+ b fx ( E 2 fc +E 2 cf +E 2 fs +E 2 sf )

Where:

I are invariants,

W is the strain potential (strain-energy function),

C is stress-scaling coefficient,

C compr is bulk modulus (kPa),

E is strain,

b ff is fiber strain exponent,

b xx is transverse strain component, and

b fx is fiber-transverse shear exponent.

9. A system as recited in claim 8 wherein the stress-scaling coefficient for Bowman's capsule (C Bowman ) is approximately five times greater than the stress-scaling coefficient for the stroma (C stroma ).

10. A system for simulating a reconfiguration of a model cornea which comprises:

a finite element model having a plurality of individual elements, wherein each element is pre-programmed with coefficients for biomechanical characteristics based on diagnostic corneal data to collectively replicate biomechanical properties of the cornea, and to represent the cornea in a first configuration wherein a first group of elements are pre-programmed elements to simulate biomechanical characteristics for Bowman's capsule of the cornea and a second group of elements are pre-programmed elements to simulate biomechanical characteristics for a stroma of the cornea, and further wherein the finite element model defines an anterior surface and a posterior surface for the cornea, with an axis perpendicular to the surfaces and passing through respective apexes of the surfaces, and further wherein the curvatures of the anterior and posterior surfaces are approximated by a respective conic section expressed as:

z

(

x

)

=

1

2

-

1

[

R

2

+

x

2

(

2

-

1

)

-

R

]

.

Where:

R for the anterior surface is approximately 7.86mm;

R for the posterior surface is approximately 6.76mm;

e for the eccentricity of the cornea is 0.32;

a computer means for reducing the coefficients of the finite element model into a range approximately eighty to ninety-five percent of the preprogrammed value to minimize designated biomechanical characteristics on a plurality of selected elements to create a reconfigured model cornea; and

a computer means for measuring the reconfigured model cornea.

11. A system as recited in claim 10 wherein the finite element model is axisymmetric and is based on a nonlinearly elastic, slightly compressible, transversely isotropic formulation with an isotropic exponential Lagrangian strain-energy function based on:

W =½ C ( e Q −1)+ C compr ( I 3 InI 3 −I 3 =1)

and

Q=b ff E 2 ff +b xx ( E 2 cc +E 2 ss +E 2 cs +E 2 sc )+ b fx ( E 2 fc +E 2 cf +E 2 fs +E 2 sf )

Where:

I are invariants,

W is the strain potential (strain-energy function),

C is stress-scaling coefficient,

C compr is bulk modulus (kPa),

E is strain,

b ff is fiber strain exponent,

b xx is transverse strain component,

b fx is fiber-transverse shear exponent, and

wherein the stress-scaling coefficient for Bowman's capsule (C Bowman ) is approximately five time greater than the stress-scaling coefficient for the stroma (C stroma ).

12. A system as recited in claim 10 wherein the finite element model defines nine layers of elements wherein three of the layers include the first group of elements and six layers include the second group of elements.

13. A system as recited in claim 10 wherein elements to be minimized are selected from the second group.

14. A method for using a computer to simulate a reconfiguration of a cornea which comprises the steps of:

creating a finite element model comprising a plurality of elements;

pre-programming the computer with a first plurality of the elements with coefficients to simulate biomechanical characteristics for Bowman's capsule of the cornea and a second plurality of the elements with coefficients to simulate biomechanical characteristics for a stroma of the cornea, wherein the pre-programmed elements are established for the finite element model according to diagnostic corneal data;

minimizing biomechanical characteristics on selected elements by reducing coefficients into a range approximately eighty to ninety-five percent of the preprogrammed value to create a reconfigured cornea;

measuring the reconfigured cornea in response to the minimizing step; and

repeating the minimizing and measuring steps, as required.

15. A method as recited in claim 14 wherein the finite element model defines an anterior surface and a posterior surface for the cornea, with an axis perpendicular to the surfaces and passing through respective apexes of the surfaces, and further wherein the curvatures of the anterior and posterior surfaces are approximated by a respective conic section expressed as:

z

(

x

)

=

1

e

2

-

1

[

R

2

+

x

2

(

e

2

-

1

)

-

R

]

.

Assignments (16)
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 073637/0001 →
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH HEALTH IRELAND LIMITED; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMA POLAND SPOLKA Z ORGANICZONA ODPOWIEDZIALNOSCIA; VALEANT SP. Z.O.O.
Reel/Frame 073637/0222 →
OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 045444/0634) Recorded Nov 2, 2022
From: THE BANK OF NEW YORK MELLON
To: BAUSCH & LOMB INCORPORATED; LABORATOIRE CHAUVIN S.A.S.; TECHNOLAS PERFECT VISION GMBH; THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Reel/Frame 061872/0295 →
OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 057821/0800) Recorded Nov 2, 2022
From: THE BANK OF NEW YORK MELLON
To: TECHNOLAS PERFECT VISION GMBH; BAUSCH + LOMB IRELAND LIMITED
Reel/Frame 061884/0514 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS (REEL/FRAME 036400/0711) Recorded Oct 26, 2022
From: BARCLAYS BANK PLC
To: BAUSCH & LOMB INCORPORATED; TECHNOLAS PERFECT VISION GMBH
Reel/Frame 061775/0826 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS (REEL/FRAME 045444/0299) Recorded Oct 26, 2022
From: BARCLAYS BANK PLC
To: BAUSCH & LOMB INCORPORATED; TECHNOLAS PERFECT VISION GMBH; THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES; PF CONSUMER HEALTHCARE 1 LLC; LABORATOIRE CHAUVIN S.A.S.
Reel/Frame 061779/0001 →
SECURITY INTEREST Recorded Oct 5, 2021
From: BAUSCH & LOMB IRELAND LIMITED; BAUSCH HEALTH COMPANIES INC.; DR. GERHARD MANN CHEM.-PHARM. FABRIK GMBH; TECHNOLAS PERFECT VISION GMBH
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 057821/0800 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jul 3, 2019
From: BAUSCH HEALTH IRELAND LIMITED; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT PHARMACEUTICALS LUXEMBOURG S.À R.L.; VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA; VALEANT SP. Z O. O.
To: THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT
Reel/Frame 049672/0652 →
SECURITY INTEREST Recorded Feb 26, 2018
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT
Reel/Frame 045444/0634 →
SECURITY INTEREST Recorded Feb 26, 2018
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 045444/0299 →
SECURITY INTEREST Recorded Jul 19, 2017
From: TECHNOLAS PERFECT VISION GMBH
To: THE BANK OF NEW YORK MELLON
Reel/Frame 043251/0910 →
SECURITY AGREEMENT Recorded Aug 20, 2015
From: TECHNOLAS PERFECT VISION GMBH; DR. GERHARD MANN CHEM-PHARM. FABRIK GMBH
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 036400/0711 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 12, 2009
From: 20/10 PERFECT VISION AG
To: TECHNOLAS PERFECT VISION GMBH
Reel/Frame 023510/0024 →
CHANGE OF NAME Recorded Aug 10, 2009
From: 20/10 PERFECT VISION OPERATIONS GMBH
To: TECHNOLAS PERFECT VISION GMBH
Reel/Frame 023075/0001 →
CHANGE OF NAME Recorded Aug 6, 2009
From: 20/10 PERFECT VISION AG
To: 20/10 PERFECT VISION OPERATIONS GMBH
Reel/Frame 023056/0984 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 29, 2008
From: BILLE, JOSEF F.; RUIZ, LUIS ANTONIO; LOESEL, FRIEDER
To: 20/10 PERFECT VISION AG
Reel/Frame 020585/0267 →